We previously identified a scFv (clone H2) specific for the p53 R175H mutant peptide (HMTEVVRHC, mutation underlined) presented on HLA-A*02:01 (R175H/A2) and showed that it can be used to generate a TCR mimic bispecific antibody (MANAbody) to target cancer cells expressing p53 R175H (5). This evidence concerns the gene TP53 and cancer.